BioSpace News Archive

Per BioSpace’s 2020 U.S. Life Sciences Salary Report and 2020 U.S. Life Sciences Diversity & Inclusion Report, men out-earn women by 19.3%, which climbs to 47.6% when looking specifically at health care. Also, only 14% of women felt that opportunities for promotion were fair compared to 23% of their male counterparts.

XyloCor Therapeutics closed an additional $22.6 million in its oversubscribed Series A financing round that will support the development of its lead gene therapy program for patients with refractory angina, a coronary artery disease.

A giant in the world of oncology has fallen. José Baselga, whose research paved the way for new treatments in different types of cancer, died Sunday.

Jerusalem’s clinical-stage pharmaceutical company Oramed Pharmaceuticals is forming a joint venture with Premas Biotech to develop novel oral COVID-19 vaccine candidates.

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for March 23, 2021.

A briefing document from the U.S. FDA cites critical safety concerns with Pfizer and Eli Lilly’s anti-NGF osteoarthritis drug tanezumab, despite the fact that clinical trials have demonstrated the agent can help patients with osteoarthritis.

AstraZeneca reported that the U.S. Phase III trial of the vaccine, AZD1222, demonstrated an efficacy of 79% at preventing symptomatic COVID-19 and 100% efficacy at preventing severe disease and hospitalization.

After touting “positive results” in December and August for its Phase III cancer drug, Tesetaxel, Odonate Therapeutics is now discontinuing drug development and closing up shop.

Roche’s checkpoint inhibitor Tecentriq (atezolizumab) hit the mark in the company’s Phase III IMpower010 trial of the drug compared to best supportive care in people with resectable early-stage lung cancer.

Pending approvals ascertain impressive growth on sight for nephrogenic systemic fibrosis treatment market